Drugs & Aging

, Volume 27, Issue 2, pp 87–94 | Cite as

ACE Inhibitor and Angiotensin II Type 1 Receptor Antagonist Therapies in Elderly Patients with Diabetes Mellitus

Are They Underutilized?
Current Opinion


Diabetes mellitus is highly prevalent in older adults in the industrialized world. These patients are at high risk of complications from diabetes, including diabetic kidney disease. ACE inhibitors and their newer cousins, angiotensin II type 1 receptor antagonists (angiotensin receptor blockers [ARBs]), are powerful medications for the prevention of progression of diabetic renal disease.

Unfortunately, among the elderly, these medications have been underutilized. The reasons for this include physician concerns regarding patient age and limited life expectancy and potential complications of ACE inhibitor or ARB use, specifically an increase in creatinine levels and hyperkalaemia.

As discussed in this article, there have been several studies that show that the effects of inhibition of the renin-angiotensin system can be beneficial for the treatment of cardiovascular disease and renal disease among elderly patients with diabetes and that the potential risks mentioned above are no greater in this group than in the general population. For these reasons, several professional societies recommend that elderly patients with diabetes and hypertension (systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg) be treated with an ACE inhibitor or ARB (as is recommended for younger diabetics). Use of ACE inhibitors or ARBs is also recommended for those with cardiovascular disease or those who are at risk of cardiovascular disease. Furthermore, in the management of diabetic kidney disease in elderly patients, treatment with ACE inhibitors or ARBs is also recommended to reduce the risk or slow the progression of nephropathy. Renal function and potassium levels should be monitored within the first 12 weeks of initiation of these medications, with each dose increase, and on a yearly basis thereafter.

This article summarizes the current guidelines on the use of ACE inhibitors and ARBs in older adults with diabetes, reviews the evidence for their use in the elderly population, and suggests potential reasons for the observed underuse of these powerful drugs in this vulnerable population.


  1. 1.
    IDF diabetes atlas. Brussels: International Diabetes Federation, 2005 [online]. Available from URL: http://www.eatlas.idf.org [Accessed 2008 May 13]
  2. 2.
    Geiss LS, Herman WH, Goldschmid MG, et al. Surveillance for diabetes mellitus: United States, 1980–1989. MMWR CDC Surveill Summ 1993; 42(2): 1–20PubMedGoogle Scholar
  3. 3.
    Centers for Disease Control and Prevention (CDC). Racial differences in trends of end-stage renal disease, by primary diagnosis: United States, 1994–2004. MMWR Morb Mortal Wkly Rep 2007; 56(11): 253–6Google Scholar
  4. 4.
    Boyle JP, Honeycutt AA, Narayan KM, et al. Projection of diabetes burden through 2050: impact of changing demography and disease prevalence in the US. Diabetes Care 2001; 24(11): 1936–40PubMedCrossRefGoogle Scholar
  5. 5.
    Harris MI, Flegal KM, Cowie CC, et al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in US adults: the Third National Health and Nutrition Examination Survey, 1988–1994. Diabetes Care 1998; 21(4): 518–24PubMedCrossRefGoogle Scholar
  6. 6.
    USRDS. Annual data report: atlas of end-stage renal disease in the US National Institutes of Health. Bethesda (MD): National Institutes of Diabetes and Digestive Kidney Diseases, 2006Google Scholar
  7. 7.
    Engelgau MM, Geiss LS, Saaddine JB, et al. The evolving diabetes burden in the United States. Ann Intern Med 2004; 140(11): 945–50PubMedGoogle Scholar
  8. 8.
    Centers for Disease Control and Prevention. Diabetes surveillance system. Atlanta (GA): US Department of Health and Human Services, 2003Google Scholar
  9. 9.
    US Centers for Disease Control and Prevention. National diabetes fact sheet: general information and national estimates on diabetes in the United State, 2005. Atlanta (GA): US Department of Health and Human Services, Centers for Disease Control and Prevention, 2005Google Scholar
  10. 10.
    American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care 2008; 31: S55–60CrossRefGoogle Scholar
  11. 11.
    Guidelines for improving the care of the older person with diabetes mellitus. California Healthcare Foundation/American Geriatrics Society Panel on Improving Care for Elders with Diabetes. J Am Geriatr Soc 2003; S1: S265–80Google Scholar
  12. 12.
    Wingard DL, Barret-Conner E. Heart disease and diabetes. In: Harris MI, Cowie CC, Stern MP, et al., editors. Diabetes in America. 2nd ed. Bethesda (MD): National Institutes of Health, 1995: 429–88Google Scholar
  13. 13.
    Hogan P, Dall T, Nikolov P, American Diabetes Association. Economic costs of diabetes in the US in 2002. Diabetes Care 2003; 26(3): 917–32PubMedCrossRefGoogle Scholar
  14. 14.
    Bjorck S, Nyberg G, Mulec H, et al. Beneficial effects of angiotensin converting enzyme inhibition on renal function in patients with diabetic nephropathy. Br Med J (Clin Res Ed) 1986; 293(6545): 471–4CrossRefGoogle Scholar
  15. 15.
    Hommel E, Parving HH, Mathiesen E, et al. Effect of captopril on kidney function in insulin-dependent diabetic patients with nephropathy. Br Med J (Clin Res Ed) 1986; 293(6545): 467–70CrossRefGoogle Scholar
  16. 16.
    Ravid M, Lang R, Rachmani R, et al. Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus: a 7-year follow-up study. Arch Intern Med 1996; 156(3): 286–9PubMedCrossRefGoogle Scholar
  17. 17.
    Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345(12): 851–60PubMedCrossRefGoogle Scholar
  18. 18.
    Lewis EJ, Hunsicker LG, Bain RP, et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993; 329(20): 1456–62PubMedCrossRefGoogle Scholar
  19. 19.
    Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345(12): 861–9PubMedCrossRefGoogle Scholar
  20. 20.
    Parving HH, Lehnert H, Brochner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345(12): 870–8PubMedCrossRefGoogle Scholar
  21. 21.
    Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003; 349(20): 1893–906PubMedCrossRefGoogle Scholar
  22. 22.
    Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342(3): 145–53PubMedCrossRefGoogle Scholar
  23. 23.
    KDOQI. KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis 2007; 49(2 Suppl. 2): S12–154Google Scholar
  24. 24.
    Winkelmayer WC, Fischer MA, Schneeweiss S, et al. Underuse of ACE inhibitors and angiotensin II receptor blockers in elderly patients with diabetes. Am J Kidney Dis 2005; 46(6): 1080–7PubMedCrossRefGoogle Scholar
  25. 25.
    Rosen AB, Karter AJ, Liu JY, et al. Use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in high-risk clinical and ethnic groups with diabetes. J Gen Intern Med 2004; 19(6): 669–75PubMedCrossRefGoogle Scholar
  26. 26.
    Dunn EJ, Burton CJ, Feest TG. The care of patients with diabetic nephropathy: audit, feedback, and improvement. QJM 1999; 92(8): 443–9PubMedCrossRefGoogle Scholar
  27. 27.
    Howard PA, Shireman TI, Dhingra A, et al. Patterns of ACE inhibitor use in elderly Medicaid patients with heart failure. Am J Geriatr Cardiol 2002; 11(5): 287–94PubMedCrossRefGoogle Scholar
  28. 28.
    Masoudi FA, Rathore SS, Wang Y, et al. National patterns of use and effectiveness of angiotensin-converting enzyme inhibitors in older patients with heart failure and left ventricular systolic dysfunction. Circulation 2004; 110(6): 724–31PubMedCrossRefGoogle Scholar
  29. 29.
    Ahmed A, Allman RM, DeLong JF, et al. Age-related underutilization of angiotensin-converting enzyme inhibitors in older hospitalized heart failure patients. South Med J 2002; 95(7): 703–10PubMedGoogle Scholar
  30. 30.
    Frances CD, Noguchi H, Massie BM, et al. Are we inhibited? Renal insufficiency should not preclude the use of ACE inhibitors for patients with myocardial infarction and depressed left ventricular function. Arch Intern Med 2000; 160(17): 2645–50PubMedCrossRefGoogle Scholar
  31. 31.
    Ahmed A, Kiefe CI, Allman RM, et al. Survival benefits of angiotensin-converting enzyme inhibitors in older heart failure patients with perceived contraindications. J Am Geriatr Soc 2002; 50(10): 1659–66PubMedCrossRefGoogle Scholar
  32. 32.
    Ahmed A, Centor RM, Weaver MT, et al. A propensity score analysis of the impact of angiotensin-convertingenzyme inhibitors on long-term survival of older adults with heart failure and perceived contraindications. Am Heart J 2005; 149(4): 737–43PubMedCrossRefGoogle Scholar
  33. 33.
    Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000; 355(9200): 253–9CrossRefGoogle Scholar
  34. 34.
    Ahuja TS, Freeman D, Mahnken Jr JD, et al. Predictors of the development of hyperkalemia in patients using angiotensin-converting enzyme inhibitors. Am J Nephrol 2000; 20(4): 268–72PubMedCrossRefGoogle Scholar
  35. 35.
    Winkelmayer WC, Zhang Z, Shahinfar S, et al. Efficacy and safety of angiotensin II receptor blockade in elderly patients with diabetes. Diabetes Care 2006; 29(10): 2210–7PubMedCrossRefGoogle Scholar
  36. 36.
    Bakris GL, Weir MR. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern? Arch Intern Med 2000; 160(5): 685–93PubMedCrossRefGoogle Scholar
  37. 37.
    Ahmed A. Use of angiotensin-converting enzyme inhibitors in patients with heart failure and renal insufficiency: how concerned should we be by the rise in serum creatinine? J Am Geriatr Soc 2002; 50(7): 1297–300PubMedCrossRefGoogle Scholar
  38. 38.
    Cooke CE, Fatodu H. Physician conformity and patient adherence to ACE inhibitors and ARBs in patients with diabetes, with and without renal disease and hypertension, in a Medicaid managed care organization. J Manag Care Pharm 2006; 12(8): 649–55PubMedGoogle Scholar

Copyright information

© Adis Data Information BV 2010

Authors and Affiliations

  • Lamioko Shika Pappoe
    • 1
  • Wolfgang C. Winkelmayer
    • 1
    • 2
  1. 1.Renal Division, Department of Medicine, Brigham and Women’s HospitalHarvard Medical SchoolBostonUSA
  2. 2.Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s HospitalHarvard Medical SchoolBostonUSA

Personalised recommendations